key: cord-0777680-j4fb6j2h authors: Spadea, Manuela; Carraro, Francesca; Saglio, Francesco; Vassallo, Elena; Pessolano, Rosanna; Berger, Massimo; Scolfaro, Carlo; Grassitelli, Sergio; Fagioli, Franca title: Successfully treated severe COVID‐19 and invasive aspergillosis in early hematopoietic cell transplantation setting date: 2020-09-29 journal: Transpl Infect Dis DOI: 10.1111/tid.13470 sha: c6847954b59e87eb0c99b2786bea87143cd40836 doc_id: 777680 cord_uid: j4fb6j2h So far, we do not have any published database regarding HCT patients during the present pandemic. We herein describe the first case of COVID-19 presenting in the early hematopoietic cell transplantation (HCT) setting. To the editor, So far, we do not have any published database regarding HCT patients during the present pandemic. We herein describe the first case of COVID-19 presenting in the early hematopoietic cell transplantation (HCT) setting. A previously healthy 19-year-old patient diagnosed and treated for ALL was then referred to our center for HCT from a full-matched unrelated donor. On February 24, 2020, he was admitted to HCT service in good clinical condition, asymptomatic, with unremarkable laboratory findings. Conditioning regimen was myeloablative; graft versus host disease (GvHD) prophylaxis included rabbit anti-thymocyte globulin (ATG), short-course methotrexate, and cyclosporine. On March 4, 2020 , peripheral blood stem cell (PBSC) infusion (day 0) was performed, without complications. On day +12, the patient presented fever, nonproductive dry cough, with normal oxygen saturations; chest radiography revealed a pulmonary infiltrate in the left middle to lower lung zones. Computed tomography (CT) scan of the chest showed a diffuse consolidative lesion in the left middle to lower lung lobes and smaller consolidative opacities in the right lower lobe with surrounding minimal groundglass opacities, suggestive for fungal infection. Galactomannan (GM) and beta-D-glucan (BDG) were positive (GM assay index 1.6; BDG assay index > 500). We could not perform a bronchoalveolar lavage because of the patient's clinical condition and thrombocytopenia. Based on revised EORTC-MSG criteria, a probable invasive aspergillosis was diagnosed. 1 Considering the previously primary prophylaxis with posaconazole, we started liposomal amphotericin B and broad-spectrum antimicrobial therapy with good response. Nevertheless, on day +25, along with neutrophil engraftment, the patient presented fever, cough, and required oxygen support We carefully screened the patient for cytokine storm, but a clear pathologic inflammatory profile was not distinguishable (Figure 2 ). In the meantime, from a graft standpoint, the patient was transfusion independent, with a good neutrophil count (neutrophils more than 1.5 × 10 9 /L, constantly). Besides, COVID-19 test persisted positive. From day +35, we administered intravenous remdesivir, for 10 days, according to the ongoing recommendations, 5 pursuing its promising therapeutic effect, rather than its efficacy in clearing viral load. 6 Unfortunately, on the last day of remdesivir treatment, the patient presented fever and the first signs of ventilatory muscles' fatigue, whereas laboratory findings were nearly stable. Thus, we started methylprednisolone (1 mg/ kg/day, from day +46) as in accordance with acute distress respira- Normal values considered as follows: C-reactive protein (CRP) < 5 mg/L, procalcitonin (PCT) < 2 ng/mL, ferritin < 110 ng/mL, D-dimer < 500 ng/mL, interleukin-6 (IL-6) < 30 pg/mL. To be noted: ferritin did not return to the normal values, albeit our patient presented higher ferritin levels even before transplant (ferritin 3000 pg/mL), as frequent in HCT patients Syndrome (IPS). 9 Thus, from day +48, we pursued the compassionate use of ruxolitinib (5 mg TID, orally, 12 days), with the aim to prevent further inflammation and to dampen lung fibrotic transformation. 10 We observed a great clinical improvement and laboratory markers reduction to the baseline, even after 48 hours after the start of the therapy, thus, avoiding intubation ( Figure 2 ). Ultimately, two consecutive COVID-19 tests returned negative (day +60, +61), while patient's respiratory function constantly improved (supplemental oxygen discontinued on day +70). Moreover, a follow-up chest CT (day +75) confirmed the considerable improvement ( Figure 1 ). Patient was discharged on day +85. Our report highlights interesting questions to debate. First, no clear source of exposure was identified in our patient. We do believe that our young man became infected before his hospital admission and, owing to the immunosuppressing therapy he received thereafter, he had a prolonged incubation period, such as some immune-suppressed patients previously described. 11, 12 Not surprisingly, our patient presented with a co-infection. However, particularly for fungal infection, reaching a proven diagnosis could be very challenging in these vulnerable cohort of patients. Indeed, the lack of specificity of fungal biomarkers comes often with the inability to perform an invasive diagnostic test (as in our case). Nevertheless, even in the case of a probable diagnosis, a targeted treatment should be promptly provided avoiding life-threatening complications. Last but not least, it is worth remarking that the administration of anti-inflammatory drugs, such as ruxolitinib, is of paramount relevance when treating such a unique cohort of severe COVID-19 patients, especially in order to prevent additional transplant-related complications. Furthermore, encouraging results regarding the efficacy and safety of ruxolitinib were presented from a randomized phase II trial. 13 Indeed, our report highlights the added value of a timely immunomodulatory therapy in preventing the development of cryptogenic organizing pneumonia as the ultimate result of COVID-19 infection. As a final remark, we strongly suggest a tailor-made approach while handling diagnosis, management, and treatment of COVID-19 and its related complications in transplanted patients. To this aim, further studies are needed. COVID-19 management, hematopoietic cell transplantation, immune suppressed patients, invasive aspergillosis co-infection, ruxolitinib, severe COVID-19 The authors thank all of the medical staff members involved in treating this patient. The authors of this manuscript have no conflicts of interest to disclose as described by the Transplant Infectious disease journal. MS and FC performed the research, collected, analyzed the data, and wrote the paper; FS, EV, CS, SG, RP, and MB collected and analyzed the data; FF critically revised the manuscript. Data sharing is not applicable to this article as no new data were created or analyzed in this study. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-A groupe de recherche respiratoire en réanimation onco-hématologique study Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Compassionate use of remdesivir for patients with severe Covid-19 Remdesivir for the treatment of Covid-19 -preliminary report SARS: systematic review of treatment effects Corticosteroid therapy for critically ill patients with middle east respiratory syndrome An official American Thoracic Society Research Statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome Exploring the relevance of senotherapeutics for the current SARS-CoV-2 emergency and similar future global health threats COVID-19 in a patient with chronic lymphocytic leukaemia COVID-19 in posttransplant patientsreport of 2 cases Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting